Norway supports Clavis with grant for pancreatic cancer trial

The Norwegian government has awarded Clavis Pharma ASA up to $1.1 million to accelerate its early clinical-stage treatment for pancreatic cancer, intravenous CP-4126. The grant was made by Innovation Norway, a state-owned company.